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Angiogenesis is likely to be involved in the pathogenesis of
endometriosis. According to the transplantation theory,
when the exfoliated endometrium is attached to the periton-
eal layer, the establishment of a new blood supply is
essential for the survival of the endometrial implant and
development of endometriosis. From the known angiogenic
factors, vascular endothelial growth factor (VEGF) has
emerged as a pivotally important regulator of normal
angiogenesis and pathological neovascularization. The
VEGF protein was evaluated immunohistochemically in the
eutopic endometrium of 10 women without endometriosis
(group I) at laparoscopy and the eutopic endometrium
and peritoneal endometriotic lesions of 43 women with
endometriosis (group II). VEGF histological scores were
9.7￿ 4.3 and 4.0￿ 2.6 respectively in the epithelium and
stroma of the eutopic endometrium of group I women, and
10.3 ￿ 2.3 and 3.6 ￿ 2.3 respectively in women of group
II. In red lesions, the VEGF scores were 11.1 ￿ 3.0 in the
epithelium and 5.1 ￿ 3.0 in the stroma, and in black
lesions were 8.6￿ 2.7 and 1.6￿ 1.6, respectively. Signific-
antly lower values were observed in black lesions as
compared with eutopic endometrium and red lesions, the
values of which were similar. Scores were also evaluated
according to the phase of the cycle. In eutopic as well as
ectopic endometrium, no significant cyclic variations were
observed throughout the cycle. However, VEGF content
was found to be higher in the eutopic glandular epithelium
of women with endometriosis during the late secretory
phase, possibly suggesting a more likely tendency to
implant. In contrast, significantly higher VEGF content
was noted in red lesions as compared with black lesions.
During all phases of the cycle, the VEGF content in stromal
cells of red lesions was higher than in black lesions.
Similarities in VEGF content were observed in the glandu-
lar epithelium of the eutopic endometrium of women with
endometriosis and red lesions, suggesting that endo-
metriosis probably arises from the peritoneal seeding of
viable endometrial cells during retrograde menstruation
and that red lesions can be considered as the first stage of
implantation. After the attachment phase, the high VEGF
levels could provoke an increase in the subperitoneal
vascular network and facilitate implantation and viability
in the retroperitoneal space. Lower VEGF levels in black
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lesions explain the decrease in both stromal vascularization,
followed by fibrosis and inactivation of the implant.
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Introduction
According to the transplantation theory, when exfoliated endo-
metrium is attached to the peritoneal layer, the establishment
of a new blood supply is essential for the survival of the
endometrial implant and the development of endometriosis
(Sampson, 1927; Nisolle and Donnez, 1996).
Angiogenesis is a fundamental process by which new blood
vessels are formed. The highly regulated angiogenesis that
occurs within the female reproductive tract is critical for
normal reproduction, including follicular maturation, selection
and normal function of the corpus luteum, and endometrial
growth and remodelling (Folkman and Klagsbrun, 1987;
Gordon et al., 1995). Unregulated angiogenesis is involved
in non-neoplastic diseases such as diabetic blindness and
rheumatoid arthritis.
Nowadays, several angiogenic factors have been identified,
including acidic and basic fibroblast growth factors (FGF-α,
FGF-β), platelet-derived endothelial cell growth factor (PD-
ECGF), transforming growth factors-α and -β (TGF-α, TGF-
β), tumour necrosis factor-α (TNF-α) and vascular endothelial
growth factor (VEGF) (Folkman and Shing, 1992).
VEGF, also known as vascular permeability factor, is a
heparin-binding glycoprotein with potent angiogenic, endothel-
ial cell-specific mitogenic and vascular permeability activities.
It has been suggested that VEGF is an important angiogenic
factor in many physiological and pathological conditions and
has recently been incriminated in the pathogenesis of capillary
leakage in ovarian hyperstimulation syndrome (Abramov et al.,
1997). The presence of VEGF has also been demonstrated
in human endometrium and it may be important in both
physiological and pathological angiogenesis (Charnock-Jones
et al., 1993; Smith, 1996).
Several authors have demonstrated higher peritoneal concen-
trations of VEGF in women with moderate to severe endo-
metriosis than in women without the disease (McLaren et al.,
1996b; Shifren et al., 1996). Nevertheless, the presence of
VEGF in endometriotic tissue is less detailed in the literature
and there is a discrepancy between the conclusions of these
studies. Indeed, although McLaren et al. (1996b) found that
VEGF expression was limited in endometriotic tissue and only
seen in individual tissue macrophages distributed throughout
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the stroma, Shifren et al. (1996) demonstrated similar VEGF
expression in both endometriosis and eutopic endometrium.
The aim of this study was to compare the VEGF content in
eutopic endometrium and black and red peritoneal lesions
throughout the menstrual cycle in order to clarify the role of
VEGF in the pathogenesis of endometriosis.
Materials and methods
In this study, 10 women without endometriosis at laparoscopy (group
I) and 43 women with laparoscopy-proven endometriosis (group II)
were evaluated. Among group II women, peritoneal biopsies of 3–5
mm in size were taken from areas with endometriotic lesions using
a biopsy punch forceps (26175 DN; Storz, Tuttligen, Germany).
Biopsies of both typical black lesions (n ￿ 29) and red flame-like
lesions (n ￿ 24) were taken. All patients had regular (28–30 days)
ovulatory cycles, and none was given hormonal therapy for at least
3 months before surgery. The mean age was 31.5 ￿ 5.0 years. In all
patients, accurate menstrual dating could be carried out according to
the last and next menstrual period and basal body temperature, and
corroborated with appropriate histological dating of endometrial
biopsies according to the criteria of Noyes et al. (1950). The
endometrial biopsies (n￿ 43) were classified as follows: proliferative
phase (PP) (days 4–14; n ￿ 16); early secretory phase (ESP) (days
15–19; n ￿ 13); mid to late secretory phase (LSP) (days 20–28;
n ￿ 14).
Biopsies from patients in group I were also classified according to
the same criteria (Noyes et al., 1950).
Measurement of VEGF staining on tissue was based on immunolab-
elling with a polyclonal antibody, which recognizes the 165, 189 and
121 amino acid splice variants of VEGF of human origin, that
are located in the cytoplasm of endometrial cells, myometrium,
macrophages of the peritoneal fluid, vascular smooth muscle and
endothelium and various cell lines (Tischer et al., 1991; Charnock-
Jones et al., 1993; McLaren et al., 1996a; Smith, 1996).
VEGF labelling was performed by immunoperoxidase techniques
using the peroxidase–antiperoxidase (PAP) complex which increases
the reliability and sensitivity of detection. Tissue samples were fixed
in 4% formaldehyde and embedded in paraffin. Thick tissue sections
(6 µm) were mounted on Superfrost Plus slides (Menzel-Gla¨zer,
Germany) and stained using the following technique. After rehydration
of the sections and inhibition of endogenous peroxidases in 0.3%
hydrogen peroxide solution, retrieval of VEGF antigens was achieved
by the microwave technique in citrate buffer. Non-specific reactivities
were inhibited by a 30 min incubation in a solution of 10% normal
goat serum (NGS; Pan Systems, NTL, Brussels, Belgium) and 1%
bovine serum albumin (BSA; Sigma, Bornem, Belgium). The sections
were then incubated in 1/100 dilution of polyclonal rabbit anti-
VEGF primary IgG antibody [VEGF (a-20); cat# sc-152, Santa Cruz
Biotechnology, Santa Cruz, California, USA) in 1% NGS/0.1% BSA
solution overnight at 4°C. The tissue was then incubated with 1%
goat anti-rabbit second antibody (code Z0421, Dako A/S, Copenhagen,
Denmark) followed by the PAP complex (code Z0113, Dako), and
then diaminobenzidine (DAB; S3000, Dako) and hydrogen peroxide
until a stable non-diffusable brown precipitate product was detectable.
Slides were lightly counterstained in hemalum. In each case, negative
controls were prepared which consisted of one section incubated
without anti-VEGF antibody.
Fluorescence double-staining for VEGF-positivemacrophage detec-
tion was carried out on some tissue sections. After the VEGF had
been identified, slides were incubated for 30 min in a 10% NGS/1%
BSA solution and then overnight at 4°C with the monoclonal mouse
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Figure 1. VEGF immunostaining. (A) In eutopic endometrium
during the early secretory phase. Bar ￿ 360 µm. (B) In a red
peritoneal lesion during the early secretory phase.
anti-human macrophage, CD68 antibody (dilution 1/50; clone KP1,
Dako). The slides were then incubated for 30 min in the dark with a
1/20 dilution of FITC-conjugated rabbit anti-mouse Ig (Dako), washed
and mounted in aqueous mounting medium.
All sections were examined on a blind basis using a Leitz Orthoplan
light microscope (Leitz, Wetzlar, Germany) with the 40￿ objective.
A semi-quantitative analysis was obtained by determination of the
distribution and the intensity of the staining within the glandular
epithelium and the stroma. The VEGF histological score (H) was
calculated as follows: H ￿ Σ Pi, where i is the intensity from 0
(negative cells) to 3 (high staining intensity); and P is the percentage
of stained cells for each given i, where P values of 1, 2, 3, 4 and 5
indicate￿15%, 15–50%, 50–85%,￿85% and 100% positive-staining
cells, respectively.
Bivariate analysis of variance was used for statistical evaluation.
Results
Biopsies taken from typical black and red peritoneal lesions
showed the presence of endometrial elements (glands and
stroma) in all cases. VEGF immunoreactivity was detected in
both the glandular epithelium and stroma of the endometrium
and peritoneal endometriotic lesions. Staining was homogen-
eous in epithelial cells but heterogeneous in stromal cells
(Figure 1).
Tables I and II represent the VEGF histological (H)-scores
found in the glandular and stromal cells of eutopic and ectopic
endometrium according to the phase of the menstrual cycle.
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Table I. VEGF histological score in the glandular cells of eutopic and ectopic endometrium according to the
phase of the menstrual cycle
Patient Over whole Proliferative Early secretory Late secretory
cycle phase phase phase
Women without endometriosis
(group I; n ￿ 10)
Eutopic endometrium 9.7 ￿ 4.3 10.3 ￿ 0.6 10.7 ￿ 3.0 6.0 ￿ 6.6
(n ￿ 10) (n ￿ 3) (n ￿ 4) (n ￿ 3)
Women with endometriosis
(group II; n ￿ 43)
Eutopic endometrium 10.3 ￿ 2.3 9.9 ￿ 2.6 10.6 ￿ 2.2a 10.1 ￿ 1.9b
(n ￿ 43) (n ￿ 16) (n ￿ 13) (n ￿ 14)
Black lesions 8.6 ￿ 2.7 8.8 ￿ 1.2 8.4 ￿ 2.7 8.8 ￿ 3.6
(n ￿ 29) (n ￿ 8) (n ￿ 12) (n ￿ 9)
Red lesions 11.1 ￿ 3.0 9.8 ￿ 4.0 12.0 ￿ 2.7a 11.3 ￿ 2.7b
(n ￿ 22) (n ￿ 6) (n ￿ 6) (n ￿ 10)
Values are means ￿ SD.
aSignificantly different from the values observed in black lesions (P ￿ 0.04).
bSignificantly different from the values observed in the eutopic endometrium of group I (P ￿ 0.04).
Table II. VEGF histological score in the stromal cells of eutopic and ectopic endometrium according to the
phase of the menstrual cycle
Patients Over whole Proliferative Early secretory Late secretory
cycle phase phase phase
Women without endometriosis
(group I; n ￿ 10)
Eutopic endometrium 4.0 ￿ 2.6a 5.7 ￿ 2.1a 3.7 ￿ 2.4b 2.7 ￿ 3.8
(n ￿ 3) (n ￿ 3) (n ￿ 4) (n ￿ 3)
Women with endometriosis
(group II; n ￿ 43)
Eutopic endometrium 3.6 ￿ 2.3a 4.0 ￿ 2.7 3.1 ￿ 1.8b 3.3 ￿ 2.1
(n ￿ 43) (n ￿ 16) (n ￿ 13) (n ￿ 14)
Black lesions 1.6 ￿ 1.6 2.0 ￿ 1.7 1.6 ￿ 1.8b 1.4 ￿ 1.3
(n ￿ 27) (n ￿ 6) (n ￿ 12) (n ￿ 9)
Red lesions 5.1 ￿ 3.0a 3.8 ￿ 1.6a 7.1 ￿ 3.9c 4.5 ￿ 2.5a
(n ￿ 24) (n ￿ 6) (n ￿ 7) (n ￿ 11)
Values are means ￿ SD.
aSignificantly different from the values observed in black lesions (P ￿ 0.03).
bSignificantly different from the values observed in red lesions (P ￿ 0.03).
cSignificantly different from the proliferative phase (P ￿ 0.05).
Group I (women without endometriosis)
The glandular VEGF H-score of eutopic endometrium was
9.7 ￿ 4.3 and similar during the different phases of the
menstrual cycle (PP, 10.3 ￿ 0.6; ESP, 10.7 ￿ 3.0; LSP,
6.0 ￿ 6.6). In the stroma, the VEGF H-score was 4.0 ￿ 2.6
and found to be lower during the late secretory phase when
compared with the proliferative and early secretory phases,
though the difference was not significant.
Group II (women with endometriosis)
In the eutopic endometrium, the glandular VEGF H-score was
10.3 ￿ 2.3 and similar during the different phases of the
menstrual cycle (PP, 9.9 ￿ 2.6; ESP, 10.6 ￿ 2.2; LSP,
10.1 ￿ 1.9). In the stroma, the VEGF H-score was 3.6 ￿ 2.3,
there being no significant cyclic variations in score throughout
the menstrual cycle (PP, 4.0 ￿ 2.7; ESP, 3.1 ￿ 1.8; LSP,
3.3 ￿ 2.1).
In black peritoneal lesions, the H-score was 8.6 ￿ 2.7 in
the epithelium and 1.6 ￿ 1.6 in the stroma. No significant
cyclic variations in VEGF H-score occurred in the glandular
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epithelium (PP, 8.8 ￿ 1.2; ESP, 8.4 ￿ 2.7; LSP, 8.8 ￿ 3.6)
or in the stroma (PP, 2.0￿ 1.7; ESP, 1.6￿ 1.8; LSP, 1.4￿ 1.3).
In red peritoneal lesions, the glandular VEGF H-score was
11.1 ￿ 3.0 and there were no significant cyclic variations in
the glandular epithelium (PP, 9.8 ￿ 4.0; ESP, 12.0 ￿ 2.7;
LSP, 11.3 ￿ 2.7). In the stroma, the VEGF H-score was
5.1 ￿ 3.0, significantly higher (P ￿ 0.03) than that observed
in black lesions (1.6 ￿ 1.6). A significant (P ￿ 0.05) increase
was observed during the early secretory phase when compared
with the proliferative phase (H-scores of 7.1 ￿ 3.9 and
3.8 ￿ 1.6, respectively).
Comparative VEGF expression of eutopic endometrium in
patients with and without endometriosis
During the proliferative and early secretory phases, the glandu-
lar VEGF H-scores in eutopic endometrium were similar in
both groups. However, during the LSP, the VEGF H-score
was significantly higher in the eutopic endometrium of endo-
metriosis patients than in control eutopic endometrium (10.1￿
1.9 and 6.0 ￿ 6.6, respectively; P ￿ 0.04).
In the stroma, no significant differences were observed
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between the VEGF H-scores found in the eutopic endometrium
of the two groups of patients throughout the menstrual cycle.
Comparative VEGF expression of black and red peritoneal
lesions
In the glandular epithelium, the VEGF H-score was signific-
antly (P ￿ 0.004) higher in red than in black peritoneal lesions
during the ESP (12.0 ￿ 2.7 and 8.4 ￿ 2.7, respectively).
During the LSP, the VEGF H-scores in red lesions (11.3￿ 2.7)
and in the eutopic endometrium (10.1 ￿ 1.9) of women with
endometriosis (group II) were significantly (P ￿ 0.04) higher
than in the eutopic endometrium of women without endo-
metriosis (6.0 ￿ 6.6) (group I).
In the stroma, the VEGF H-score was significantly (P ￿
0.03) higher in red lesions during the LSP than in black lesions
(4.5 ￿ 2.5 and 1.4 ￿ 1.3, respectively). Macrophages were
present and they were VEGF- and CD68-positive; however,
the presence of VEGF-positive and CD68-negative cells in
our study proved the immunoreactivity of the stromal cells in
the endometrium as well as in the peritoneal endometriotic
lesions.
Discussion
Although the aetiology of endometriosis is unknown, it is
generally accepted that the condition is a result of the implanta-
tion of exfoliated endometrium, deposited in the peritoneal
cavity following retrograde menstruation (Sampson, 1927).
When the exfoliated endometrium enters the peritoneal cavity
and becomes attached to the mesothelial layer through attach-
ment proteins like the cadherins, a process of angiogenesis is
essential for further implantation and the development of
peritoneal endometriosis (Nisolle and Donnez, 1996). Angio-
genesis is dependent on soluble factors released from cells
(Folkman and Klagsbrun, 1987; Gordon et al., 1995; Smith,
1996). Several peptide growth factors, including FGF-α, FGF-
β, PD-ECGF and VEGF, stimulate vascular endothelial cell
growth in vitro and angiogenesis in vivo (Gordon et al., 1995).
VEGF is a member of a family of heparin-binding proteins
that acts directly on endothelial cells to induce proliferation
and angiogenesis (Folkman and Klagsbrun, 1987; Folkman
and Shing, 1992; Gordon et al., 1995) and was found to be
the only growth factor which stimulated the growth of human
decidual endothelial cells maintained in culture; thus, VEGF
was considered essential in uterine angiogenesis (Grimwood
et al., 1995). Several sources of VEGF have been suggested,
including peritoneal macrophages, the number and activation/
secretory activity of which are increased in uterine endomet-
rium and endometriotic tissue (Gordon et al., 1995; Smith,
1996; Smith et al., 1996).
In the human endometrium, Smith (1996) and Shifren et al.
(1996) described cyclic changes in the distribution of VEGF
and mRNA expression throughout the cycle and suggested
that VEGF expression is under steroid control, being up-
regulated in response to oestradiol (Greb et al., 1997). In
contrast, McLaren et al. (1996a) observed low expression of
VEGF, mostly seen in macrophages distributed throughout the
stroma of endometriotic lesions.
In the present study, the VEGF content in the glandular
1689
epithelium and stroma of eutopic endometrium and endometri-
otic lesions was compared immunohistochemically, and thus
permitted a clear distinction between black and red peritoneal
lesions (Donnez et al., 1996; Nisolle and Donnez, 1997).
In the group of patients without endometriosis, there were
no significant variations in VEGF content in the eutopic
glandular epithelium or stroma throughout the menstrual cycle.
However, differences were noted between the eutopic endomet-
rium of women with and without endometriosis. Indeed, in
the present study, VEGF content was significantly higher in
the eutopic glandular epithelium of endometriosis patients
during the late secretory phase, suggesting that the endomet-
rium of women with endometriosis is more likely to implant
than that of women without endometriosis.
During the luteal phase, significantly higher levels of VEGF
immunostaining were observed in both the glandular epithelium
and stroma of red peritoneal endometriotic lesions as compared
with black lesions, suggesting an active angiogenic process in
red lesions, like that in eutopic endometrium. In contrast, black
lesions were characterized by a poor angiogenesis, a fact which
confirms the differences in the stromal vascularization index
between red and black lesions observed in a previous study
(Nisolle et al., 1993). The similar VEGF content found in red
lesions and eutopic glandular epithelium is another argument
in favour of the transplantation theory. Red lesions must
therefore be considered as the first stage of endometriosis and
as freshly implanted lesions.
Our results are not in accordance with those of McLaren
et al. (1996a) who reported that, in ectopic endometrium,
VEGF immunoreactivity was localized mainly on isolated cells
within the stroma and only weak staining was present on the
glandular epithelium. Moreover, using double immunofluores-
cence staining with the macrophage marker CD14 and VEGF,
they also demonstrated that individual VEGF-positive cells
within the stroma were macrophages. However, in their study,
only eight endometriotic lesions were analysed and the macro-
scopic appearance was not mentioned. It is possible that only
black lesions were analysed. By contrast, our study clearly
demonstrated that in red lesions, VEGF-positive cells included
not only macrophages, but also numerous stromal cells.
The fact that red lesions are characterized by high concentra-
tions of VEGF and the presence of matrix metalloproteinases
(MMP-1) throughout the cycle (Kokorine et al., 1997) could
be the key point of the transplantation theory. Indeed, under
the influence of MMP-1, partial shedding of red lesions and
their implantation elsewhere in the peritoneal cavity under the
influence of VEGF could explain the development of peritoneal
endometriosis.
On the basis of our data, we suggest that the eutopic
endometrium itself plays a crucial role in the histogenesis of
endometriosis. Indeed, during retrograde menstruation, endo-
metrial implants with high VEGF-expressing glandular cells
enter the peritoneal cavity. This high VEGF content found in
the glandular cells of menstruating endometrium was also
noted by Smith (1996). That the attachment phase is influenced
by the presence of attachment proteins and MMP-1 has been
confirmed in two of our other studies (Beliard et al., 1997;
Kokorine et al., 1997). Indeed, we observed a correlation
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Figure 2. Hypothesis of the histogenesis of peritoneal
endometriosis: the role of eutopic endometrium.
between MMP-1 expression and the activity of endometriotic
tissue, suggesting its involvement in tissue remodelling and
bleeding, and possibly also in the secondary shedding and
reimplantation of endometriotic lesions. In tumour angiogen-
esis, the tumour cells release angiogenic molecules such as
VEGF but they may not be the sole source of angiogenic
molecules. Tumours may recruit macrophages and then activate
them to secrete angiogenic activity—the same mechanism as
can be suggested in endometriosis. After the attachment phase,
high VEGF concentrations could provoke an increase in the
subperitoneal vascular network and facilitate implantation and
viability. Moreover, VEGF, in addition to being angiogenic,
causes increased permeability of the capillary bed and, in
similar fashion to the mechanisms involved in pathologic
angiogenesis, this could suggest that in freshly implanted
endometriotic lesions, the higher expression of VEGF might
explain a higher permeability of the capillary bed (Folkman
and Shing, 1992). This may lead to a leakage of fibrin products
into the extracellular space which will increase the recruitment
of macrophages, the angiogenic activity of which is increased
by the secretion of TNF-α, that is known to be secreted by
macrophages when these cells are activated by large molecules
such as bacterial endotoxins or fibrin products (Figure 2).
It could be hypothesized that active red endometriosis
undergoing cycling and with high concentrations of VEGF
may help the implant to revascularize and proliferate and this,
to some extent, explains the high concentrations of VEGF in
peritoneal fluid observed in several studies (Shifren et al.,
1996; McLaren et al., 1996b).
In conclusion, angiogenesis is considered as an important
step in the implantation and development process of menstrual
endometrial fragments entering the peritoneal cavity. The high
content of VEGF, as demonstrated in our study, has led to the
hypothesis that VEGF-induced angiogenesis may be a critical
aspect of the pathophysiology of this disease and suggests, as
Smith (1996) already has, that anti-angiogenic therapies could
be considered as a new clinical approach to this disease. A
recent animal study demonstrated the anti-angiogenic effects
of mifepristone via suppression of VEGF production (Greb
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et al., 1997) and there is now a need to initiate prospective
clinical studies to support this hypothesis.
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